Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Multi-center, Randomized, Active-control, Non-inferiority Study Comparing Fibrinogen Concentrate With Cryoprecipitate for the Treatment of Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients

Next Previous
Trial Profile

Prospective, Multi-center, Randomized, Active-control, Non-inferiority Study Comparing Fibrinogen Concentrate With Cryoprecipitate for the Treatment of Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Afibrinogenaemia
  • Focus Therapeutic Use
  • Acronyms FIBRES

Most Recent Events

  • 01 Aug 2024 According to an Octapharma media release, company announced the expanded approval of fibryga Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD) by the U.S. Food and Drug Administration (FDA) based on the results of FIBRES trial.
  • 27 Jun 2022 Results of post hoc analysis comparing fibrinogen concentrate (4 g) to cryoprecipitate, published in the British Journal of Anaesthesia
  • 14 Sep 2021 Results (n=415) of post-hoc analysis of FIBRES study comparing fibrinogen concentrate with cryoprecipitate in bleeding cardiac surgical patients published in the Canadian Journal of Anesthesia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top